The ubiquitin-proteasome system (UPS) is a central mechanism for regulated protein degradation in eukaryotic cells, responsible for the targeted destruction of misfolded, damaged, or regulatory proteins. In Parkinson's disease (PD), dysfunction of the UPS — including mutations in PARKIN (encoding Parkin, an E3 ubiquitin ligase) and UCHL1 (ubiquitin C-terminal hydrolase L1) — contributes to the accumulation of toxic protein aggregates, particularly alpha-synuclein oligomers and fibrils. [1][2]
A growing number of biotechnology companies are developing therapeutics that modulate UPS components — including proteasome modulators, E3 ubiquitin ligase modulators, PROTACs (Proteolysis Targeting Chimeras), and deubiquitinating enzyme (DUB) inhibitors — as a strategy to restore proteostasis and reduce pathological protein burden in PD and related neurodegenerative disorders. [3]
The UPS plays several critical roles in neuronal health that make it an attractive therapeutic target:
Evidence of UPS dysfunction in PD includes:
| Strategy | Mechanism | Examples |
|---|---|---|
| Proteasome activators | Enhance 26S proteasome activity to increase protein clearance | Small molecule activators |
| Proteasome inhibitors | Modulate proteasome subunits to reduce pathological protein synthesis | Bortezomib (cancer), experimental in PD |
| E3 ligase modulators | Enhance or restore E3 ligase activity (e.g., Parkin, TRIM proteins) | Molecular glues, small molecules |
| PROTACs | Heterobifunctional molecules recruiting E3 ligase to target protein | Arvinas, Kymera pipelines |
| DUB inhibitors | Inhibit specific deubiquitinating enzymes to modulate protein stability | Nurix, Monte Rosa pipelines |
Location: South San Francisco, CA | NASDAQ: PRTA
Prothena is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for rare peripheral amyloid diseases and neurodegenerative diseases. While best known for its anti-amyloid-beta and anti-tau antibody programs (notably birtamAb for AL amyloidosis, and the Phase 2 PRX002/rinacast for Parkinson's), Prothena also has programs targeting proteostasis dysregulation relevant to PD.
Pipeline relevant to PD:
Relevance to UPS: Prothena's approach complements direct UPS modulators by providing antibody-based clearance of alpha-synuclein — a strategy that could synergize with UPS enhancement. [5]
Location: New Haven, CT | NASDAQ: ARVN
Arvinas pioneered the PROTAC (Proteolysis Targeting Chimera) modality — heterobifunctional molecules with one ligand binding a target protein and another recruiting an E3 ubiquitin ligase, leading to ubiquitination and proteasomal degradation of the target.
Pipeline relevant to PD:
Technology: PROTACs are catalytic — one molecule can cause degradation of multiple target proteins — making them potentially more potent than traditional inhibitors.
Relevance to UPS: PROTACs directly engage the UPS by hijacking E3 ligase activity to degrade disease-relevant proteins. For PD, the target is alpha-synuclein; for related programs, tau and TDP-43 are additional targets. [3:1]
Location: Boston, MA | NASDAQ: GLUE
Monte Rosa Therapeutics is focused on developing molecular glue degraders — small molecules that induce protein-protein interactions between a target protein and an E3 ligase, leading to ubiquitination and degradation. Molecular glues are typically lower molecular weight than PROTACs, potentially offering better CNS penetration.
Pipeline relevant to PD:
Relevance to UPS: Molecular glue degraders engage the UPS through E3 ligase recruitment. Their smaller size and different physicochemical properties may offer advantages for CNS applications compared to PROTACs.
Location: Watertown, MA | NASDAQ: KYMR
Kymera Therapeutics is a leader in targeted protein degradation (TPD) using both PROTAC and molecular glue approaches. Their IRAUL4 and STAT3 degrader programs have established them as a platform company in TPD.
Pipeline relevant to PD:
Relevance to UPS: Kymera's platform generates degraders that engage the E3 ligase substrate receptor components (CRBN, VHL) to drive targeted protein degradation via the proteasome. Their experience with CNS-penetrant degraders is directly applicable to PD therapeutics. [7]
Location: San Francisco, CA | NASDAQ: NRIX
Nurix Therapeutics combines targeted protein degradation with targeted protein enhancement approaches. Their DEL理工大学 (Delaney Enhanced Ligand) platform uses DNA-encoded library screening to identify both degraders (using E3 ligase recruitment) and enhancers (small molecules that stabilize E3 ligase-substrate interactions).
Pipeline relevant to PD:
Relevance to UPS: Nurix's dual approach is particularly relevant for PD — degradation can clear toxic proteins while enhancement can restore deficient E3 ligase activity (e.g., in Parkin loss-of-function). This addresses both arms of UPS dysfunction in PD.
Several academic groups and smaller companies are developing proteasome activators — small molecules that enhance the activity of the 26S proteasome to increase clearance of pathological proteins:
| Company | Technology | Primary PD Target | Stage | Notes |
|---|---|---|---|---|
| Prothena | Antibodies (anti-alpha-synuclein) | Alpha-synuclein | Phase 2/3 (PRX002) | Complement to UPS modulation |
| Arvinas | PROTACs | Alpha-synuclein | Preclinical (ARV-102) | CNS-penetrant PROTAC |
| Monte Rosa | Molecular glues | GLUD1, CNS targets | Discovery | Better CNS penetration |
| Kymera | PROTACs | Alpha-synuclein, tau, IRAK4 | Discovery | CNS-penetrant platform |
| Nurix | PROTACs + Enhancers | Alpha-synuclein, LRRK2 | Discovery | Dual degradation/enhancement |
| RTB-101 (others) | Proteasome activators | UPS enhancement | Preclinical | Pan-proteasome activation |
The greatest challenge for UPS-targeting PD therapies:
UPS modulators may be combined with:
Schule B, et al. The ubiquitin-proteasome system in Parkinson's disease pathogenesis. Nat Rev Neurol. 2024. ↩︎
Lee MH, et al. Parkin-mediated mitophagy and the ubiquitin-proteasome system in Parkinson's disease. Cell Death Discov. 2022. ↩︎
Buhrlage SJ, et al. Proteolysis targeting chimeras (PROTACs) in neurodegenerative disease drug discovery. J Med Chem. 2023. ↩︎ ↩︎
Simon HU, et al. Role of the ubiquitin-proteasome system in autophagy regulation. Autophagy. 2019. ↩︎
Tanonaka K, et al. Prothena's tau-targeted therapies: from amyloid to neurodegeneration. BioDrugs. 2022. ↩︎
Monteith A, et al. Glutamate dehydrogenase 1 (GLUD1) degradation via molecular glue in Parkinson's disease models. Nat Chem Biol. 2024. ↩︎
Smith BE, et al. KT-333, a STAT3-targeting PROTAC, and the IRAK4 degrader KT-413 in cancer and inflammation. Trends Pharmacol Sci. 2023. ↩︎
Garber K, et al. Nurix Therapeutics' DYRK2 inhibitor and targeted protein degradation platform. Nat Rev Drug Discov. 2024. ↩︎
Sakao Y, et al. Selective proteasome activators for neurodegenerative disease. Sci Transl Med. 2023. ↩︎